Deferasirox, Vitamin D and Azacitidine
Phase 1/2UNKNOWN 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Deferasirox, Vitamin D and Azacitidine
Deferasirox, Vitamin D and Azacitidine is a phase 1/2 stage product being developed by Novartis for MDS. The current trial status is unknown. This product is registered under clinical trial identifier NCT01718366. Target conditions include MDS.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01718366 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 25 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| KRN321 | Kyowa Kirin | Phase 2 | 52 |
| Azacitidine + Venetoclax | AbbVie | Phase 1 | 33 |
| venetoclax + azacitidine | AbbVie | Phase 1 | 33 |
| Venetoclax + Azacitidine + Placebo | AbbVie | Phase 3 | 77 |
| venetoclax + azacitidine +/- donor lymphocyte infusion | AbbVie | Phase 1/2 | 41 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Azacitidine and LDE255 | Novartis | Phase 1 | 33 |
| MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine) | Novartis | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| Azacitidine + Azacitidine plus Deferasirox | Novartis | Phase 2 | 52 |
| LGH447 + LGH447 + midostaurin | Novartis | Phase 1 | 33 |
| Panobinostat | Novartis | Phase 1 | 33 |
| sabatolimab + azacitidine + venetoclax | Novartis | Phase 2 | 52 |
| LBH589 + Epoetin Alfa | Novartis | Phase 2 | 52 |
| Placebo + Romiplostim | Amgen | Phase 2 | 51 |
| Darbepoetin alfa + Placebo | Amgen | Phase 3 | 76 |
| Darbepoetin Alfa | Amgen | Phase 3 | 76 |